What role does MTHFR play in allergy?

MTHFR (methylenetetrahydrofolate reductase) is a key enzyme in folate metabolism, converting homocysteine to methionine. Common polymorphisms, notably C677T and A1298C, reduce enzyme activity and can lead to elevated homocysteine. Some studies have explored a potential link between MTHFR variants and allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis. The proposed mechanism involves altered DNA methylation and immune dysregulation, possibly affecting IgE synthesis. However, the evidence is inconsistent. While some observational studies report weak associations between the C677T variant and asthma or atopy, others find no significant relationship. Meta-analyses suggest a modestly increased risk, but effect sizes are small and confounded by folate status, ethnicity, and environmental factors. No causal role has been established. From a clinical perspective, MTHFR genotyping is not recommended for allergy risk assessment or management. Elevated homocysteine may be a nonspecific marker, but it does not confirm an allergic predisposition. Despite marketing claims for methylfolate supplements, there is no robust evidence from randomized controlled trials that targeting MTHFR improves allergic outcomes. Consumers should be cautious of direct-to-consumer genetic tests that overinterpret MTHFR variants. Allergy diagnosis and treatment should follow established guidelines, focusing on allergen avoidance, pharmacotherapy, and immunotherapy where appropriate. MTHFR status alone is not a reliable indicator of allergy risk or a guide for intervention.